Related Experiment Video
Updated: Jun 25, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Molecular perspectives on the non-responder phenomenon
1LIFE Biosystems GmbH, Poststrasse 34, Heidelberg 69115, Germany. jackson@lifebiosystems.com
Drug Discovery Today
|February 10, 2009
Summary
Targeted cancer therapies offer promise, but many patients show intrinsic resistance. Research now focuses on understanding non-responsive behaviors and molecular causes to improve treatment strategies and clinical decision-making.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Therapeutics
Background:
- Targeted therapies are revolutionizing cancer care with the potential for improved patient outcomes.
- However, a significant challenge remains: intrinsic resistance to these therapies in a majority of patients.
- Understanding this resistance is crucial for advancing clinical oncology.
Purpose of the Study:
- To characterize non-responsive system behavior in patients undergoing targeted therapy.
- To identify causative molecular insults contributing to therapeutic resistance.
- To inform clinical decision-making and regulatory guidance for targeted cancer treatments.
Main Methods:
- Retrospective analysis of clinical tissue samples.
- Examination of associated patient outcome data.
- Characterization of target and system-based aberrations.
Main Results:
- A complex picture of cancer-specific aberrations contributing to refractory tumor behavior has emerged.
- Numerous molecular insults and system-based aberrations are linked to treatment resistance.
- Current targeted therapies have limited clinical response/relapse rates in many patients.
Conclusions:
- Intrinsic resistance to targeted therapies is a major hurdle in oncology.
- Further research into molecular mechanisms of resistance is essential.
- Collaboration between clinicians, regulators, and sponsors is needed to integrate new knowledge into clinical practice and regulatory frameworks.
Related Concept Videos
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...